Cargando…

Real-World Use of Oritavancin for the Treatment of Osteomyelitis

Osteomyelitis is a difficult-to-treat disease that can require both surgical debridement and a prolonged course of antimicrobial therapy. Current standard of care for the antimicrobial treatment of osteomyelitis is fraught with multiple challenges and limitations. Patients typically require the inse...

Descripción completa

Detalles Bibliográficos
Autores principales: Scoble, Patrick J., Reilly, Joseph, Tillotson, Glenn S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334326/
https://www.ncbi.nlm.nih.gov/pubmed/32588387
http://dx.doi.org/10.1007/s40801-020-00194-8
_version_ 1783553915257618432
author Scoble, Patrick J.
Reilly, Joseph
Tillotson, Glenn S.
author_facet Scoble, Patrick J.
Reilly, Joseph
Tillotson, Glenn S.
author_sort Scoble, Patrick J.
collection PubMed
description Osteomyelitis is a difficult-to-treat disease that can require both surgical debridement and a prolonged course of antimicrobial therapy. Current standard of care for the antimicrobial treatment of osteomyelitis is fraught with multiple challenges and limitations. Patients typically require the insertion of an indwelling catheter for single or multiple daily intravenous antibiotic infusions for up to 6 weeks. Currently, there are treatment guidelines for only vertebral osteomyelitis, indicating the complexity of the condition. Oritavancin is a long-acting, second-generation lipoglycopeptide, administered intravenously once per week, which has potential to be a useful alternative in the treatment of osteomyelitis. This article reviews occurrence and outcomes of off-label oritavancin use for treatment of osteomyelitis as described in case reports. Analysis included 23 patients treated for osteomyelitis with single- or multiple-dose oritavancin. Overall, clinical cure or improvement was achieved in 87% of patients, and adverse events were mild and reported in only two patients. Clinical efficacy was demonstrated in 81.8% of methicillin-resistant Staphylococcus aureus (MRSA), 71.4% of methicillin-sensitive S. aureus (MSSA), 50% of vancomycin-resistant Enterococcus (VRE), and in the single case of Streptococcus pyogenes. Oritavancin has shown efficacy against Gram-positive pathogens in osteomyelitis, and offers a possible outpatient treatment option for osteomyelitis patients. Future studies are needed to determine dosing frequency in osteomyelitis patients.
format Online
Article
Text
id pubmed-7334326
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-73343262020-07-09 Real-World Use of Oritavancin for the Treatment of Osteomyelitis Scoble, Patrick J. Reilly, Joseph Tillotson, Glenn S. Drugs Real World Outcomes Review Article Osteomyelitis is a difficult-to-treat disease that can require both surgical debridement and a prolonged course of antimicrobial therapy. Current standard of care for the antimicrobial treatment of osteomyelitis is fraught with multiple challenges and limitations. Patients typically require the insertion of an indwelling catheter for single or multiple daily intravenous antibiotic infusions for up to 6 weeks. Currently, there are treatment guidelines for only vertebral osteomyelitis, indicating the complexity of the condition. Oritavancin is a long-acting, second-generation lipoglycopeptide, administered intravenously once per week, which has potential to be a useful alternative in the treatment of osteomyelitis. This article reviews occurrence and outcomes of off-label oritavancin use for treatment of osteomyelitis as described in case reports. Analysis included 23 patients treated for osteomyelitis with single- or multiple-dose oritavancin. Overall, clinical cure or improvement was achieved in 87% of patients, and adverse events were mild and reported in only two patients. Clinical efficacy was demonstrated in 81.8% of methicillin-resistant Staphylococcus aureus (MRSA), 71.4% of methicillin-sensitive S. aureus (MSSA), 50% of vancomycin-resistant Enterococcus (VRE), and in the single case of Streptococcus pyogenes. Oritavancin has shown efficacy against Gram-positive pathogens in osteomyelitis, and offers a possible outpatient treatment option for osteomyelitis patients. Future studies are needed to determine dosing frequency in osteomyelitis patients. Springer International Publishing 2020-06-25 /pmc/articles/PMC7334326/ /pubmed/32588387 http://dx.doi.org/10.1007/s40801-020-00194-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review Article
Scoble, Patrick J.
Reilly, Joseph
Tillotson, Glenn S.
Real-World Use of Oritavancin for the Treatment of Osteomyelitis
title Real-World Use of Oritavancin for the Treatment of Osteomyelitis
title_full Real-World Use of Oritavancin for the Treatment of Osteomyelitis
title_fullStr Real-World Use of Oritavancin for the Treatment of Osteomyelitis
title_full_unstemmed Real-World Use of Oritavancin for the Treatment of Osteomyelitis
title_short Real-World Use of Oritavancin for the Treatment of Osteomyelitis
title_sort real-world use of oritavancin for the treatment of osteomyelitis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334326/
https://www.ncbi.nlm.nih.gov/pubmed/32588387
http://dx.doi.org/10.1007/s40801-020-00194-8
work_keys_str_mv AT scoblepatrickj realworlduseoforitavancinforthetreatmentofosteomyelitis
AT reillyjoseph realworlduseoforitavancinforthetreatmentofosteomyelitis
AT tillotsonglenns realworlduseoforitavancinforthetreatmentofosteomyelitis